Interview with Jenny Winter, Managing Director, AstraZeneca Hungary
The Hungarian pharmaceutical environment has been undergoing many changes recently, such as a sales tax increase to 20%. Do you feel this is a climate of threat to MNCs in…
Address: 1113 Budapest, Bocskai út 134-146. Hungary,Hungary
Tel: +36 1 883 6500
Web: http://www.astrazeneca.hu/
We are active in over 100 countries with a growing presence in emerging markets including China, Brazil, Mexico and Russia.
We employ over 61,000 people (46% in Europe, 24% in the North America, 7% in Latin America and 24% in Asia, Africa and Australasia).
We invest over $4 billion in R&D each year. Around 15,7001 people work in our R&D organisation and we have 14 major R&D centres in eight countries, including Sweden, the US and the UK.
We have 9,300 employees at 23 supply and manufacturing sites in 16 countries.
In 2010, our worldwide sales totalled over $33 billion (including 10 medicines with sales of over $1 billion each).
Alongside our commitment to competitiveness and performance, we continue to be led by our core values to deliver business success responsibly. We are positioned in the top 8% in the sector in the Dow Jones World and STOXX (European) Sustainability Indexes.
We focus our skills and resources on six important areas of healthcare, which include some of the world’s most serious illnesses:
– Cardiovascular
– Gastrointestinal
– Infection
– Neuroscience
– Oncology
– Respiratory
The Hungarian pharmaceutical environment has been undergoing many changes recently, such as a sales tax increase to 20%. Do you feel this is a climate of threat to MNCs in…
You founded HYD almost 20 years ago, in 1992. Can you first explain to our readers why you made the switch from doing research at the Hungarian Institute of Oncology…
Hungary has been recognized as one of the largest pharmaceutical and healthcare markets in Central and Eastern Europe, and can obviously not be ignored by Roche. First of all, can…
You took over as GM back in 2008. No doubt that this was a challenging time to run a business, in particular in view of the external economic environment. Can…
The Hungarian pharmaceutical environment has been undergoing a turbulent time recently, with many new measures being implement by the Government. What are your observations, and how do you expect companies…
Assign Group started in 2002 as a small local CRO company founded in Austria; monitoring and doing minor project management only. Why was Austria chosen as the headquarters? First, it…
With approximately $90 billion flowing into the country (according to the Hungarian Investment and Trade Agency) since it abolished its centrally planned economy and transformed into an open, pro-business economy…
Taking a look at the voices of the pharmaceutical industry in Hungary, we see AIPM and MAYGOSZ as the 2 key associations. And while MAGYOSZ already represents many generic players……
IMS is a strong brand name when it comes to pharma and healthcare information worldwide. Can you please elaborate on the particularities that set the Hungarian pharmaceutical market apart from…
The Hungarian pharmaceutical environment has been undergoing many changes recently, such as a sales tax increase to 20%. Do you feel this is a climate of threat to MNCs in…
Hungary is one of the largest pharmaceutical markets in the region, and has been used by Janssen-Cilag as a hub. Can you elaborate on how important Hungary is for Janssen-Cilag…
Talking to Cegedim means talking to one of the experts in local market knowledge. Can you tell our readers from your point of view what really distinguishes Hungary from other…
Looking at Boehringer Ingelheim (BI) in Hungary, at first glance we see a company with a presence of already 20 years, which basically means an entry into this market right…
See our Cookie Privacy Policy Here
